Jonathan Eric Leeman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiosurgery | 17 | 2023 | 1329 | 5.190 |
Why?
|
Radiotherapy, Intensity-Modulated | 8 | 2021 | 806 | 2.450 |
Why?
|
Prostatic Neoplasms | 13 | 2024 | 11124 | 1.400 |
Why?
|
Head and Neck Neoplasms | 11 | 2019 | 2734 | 1.180 |
Why?
|
Neoplasms, Second Primary | 4 | 2023 | 1061 | 1.160 |
Why?
|
Skull Base Neoplasms | 2 | 2018 | 284 | 0.950 |
Why?
|
Carcinoma, Renal Cell | 3 | 2023 | 3143 | 0.930 |
Why?
|
Papillomavirus E7 Proteins | 2 | 2021 | 123 | 0.900 |
Why?
|
Oropharyngeal Neoplasms | 3 | 2017 | 477 | 0.880 |
Why?
|
Radiation Injuries | 4 | 2023 | 1180 | 0.850 |
Why?
|
Kidney Neoplasms | 3 | 2023 | 4262 | 0.830 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 10 | 2023 | 1624 | 0.790 |
Why?
|
Radioimmunotherapy | 1 | 2019 | 91 | 0.660 |
Why?
|
Brachytherapy | 3 | 2021 | 1248 | 0.630 |
Why?
|
Coronavirus | 1 | 2020 | 158 | 0.620 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 262 | 0.610 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2017 | 286 | 0.600 |
Why?
|
September 11 Terrorist Attacks | 1 | 2018 | 113 | 0.590 |
Why?
|
Radiotherapy, Conformal | 2 | 2019 | 548 | 0.580 |
Why?
|
Radiotherapy Dosage | 10 | 2023 | 2879 | 0.580 |
Why?
|
Prostatectomy | 3 | 2020 | 1890 | 0.560 |
Why?
|
Carcinoma | 2 | 2018 | 2375 | 0.530 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2017 | 234 | 0.510 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2023 | 9239 | 0.500 |
Why?
|
Immunomodulation | 1 | 2019 | 541 | 0.500 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1170 | 0.500 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2021 | 4034 | 0.420 |
Why?
|
Spinal Neoplasms | 2 | 2016 | 760 | 0.420 |
Why?
|
Microbubbles | 4 | 2013 | 128 | 0.400 |
Why?
|
Prostate | 4 | 2023 | 1774 | 0.390 |
Why?
|
Ultrasonic Therapy | 1 | 2012 | 235 | 0.360 |
Why?
|
Brain Stem Neoplasms | 1 | 2012 | 204 | 0.360 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2023 | 3760 | 0.350 |
Why?
|
Neoplasm Staging | 10 | 2019 | 11031 | 0.350 |
Why?
|
Brain Edema | 1 | 2013 | 617 | 0.340 |
Why?
|
Endoscopy | 1 | 2018 | 1785 | 0.320 |
Why?
|
Sarcoma | 2 | 2016 | 1897 | 0.300 |
Why?
|
Misonidazole | 2 | 2017 | 34 | 0.300 |
Why?
|
Neurosurgical Procedures | 1 | 2018 | 2002 | 0.300 |
Why?
|
Thromboembolism | 1 | 2012 | 986 | 0.270 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5256 | 0.260 |
Why?
|
Prospective Studies | 10 | 2024 | 53288 | 0.260 |
Why?
|
Prostate-Specific Antigen | 4 | 2024 | 2494 | 0.260 |
Why?
|
Humans | 56 | 2024 | 744343 | 0.250 |
Why?
|
Male | 39 | 2024 | 350118 | 0.250 |
Why?
|
Lymphatic Metastasis | 3 | 2017 | 2924 | 0.250 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2023 | 1770 | 0.230 |
Why?
|
Urogenital System | 1 | 2023 | 86 | 0.230 |
Why?
|
Adenocarcinoma | 2 | 2022 | 6364 | 0.230 |
Why?
|
Thrombolytic Therapy | 1 | 2012 | 2161 | 0.220 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 2 | 2013 | 39 | 0.220 |
Why?
|
Neoplasms | 4 | 2021 | 21683 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
Papillomavirus Infections | 4 | 2021 | 1587 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
Propensity Score | 2 | 2021 | 1781 | 0.210 |
Why?
|
Lung Neoplasms | 4 | 2023 | 13102 | 0.210 |
Why?
|
Kaplan-Meier Estimate | 6 | 2019 | 6538 | 0.210 |
Why?
|
Aged, 80 and over | 16 | 2020 | 57776 | 0.200 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 268 | 0.200 |
Why?
|
Middle Aged | 26 | 2023 | 213383 | 0.190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 11524 | 0.180 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.180 |
Why?
|
Radiometry | 3 | 2020 | 800 | 0.180 |
Why?
|
Aged | 24 | 2020 | 163280 | 0.180 |
Why?
|
Radiation Pneumonitis | 1 | 2020 | 104 | 0.180 |
Why?
|
Oncogene Proteins, Viral | 1 | 2021 | 362 | 0.180 |
Why?
|
Papillomaviridae | 4 | 2021 | 1119 | 0.180 |
Why?
|
Retrospective Studies | 17 | 2023 | 77449 | 0.170 |
Why?
|
Urethra | 1 | 2021 | 408 | 0.170 |
Why?
|
Probability | 2 | 2022 | 2505 | 0.170 |
Why?
|
Breast Neoplasms | 2 | 2023 | 20822 | 0.170 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2019 | 876 | 0.170 |
Why?
|
Jaw | 1 | 2019 | 96 | 0.170 |
Why?
|
Tonsillar Neoplasms | 1 | 2019 | 51 | 0.170 |
Why?
|
Lung | 2 | 2020 | 9856 | 0.170 |
Why?
|
Follow-Up Studies | 10 | 2019 | 39050 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 221 | 0.160 |
Why?
|
DNA Breaks, Double-Stranded | 2 | 2021 | 594 | 0.160 |
Why?
|
Tumor Burden | 3 | 2023 | 1915 | 0.160 |
Why?
|
Laryngeal Neoplasms | 1 | 2022 | 512 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 9 | 2023 | 35421 | 0.160 |
Why?
|
Androgen Antagonists | 2 | 2024 | 1377 | 0.160 |
Why?
|
Disease-Free Survival | 5 | 2019 | 6895 | 0.150 |
Why?
|
Oxygen Consumption | 1 | 2023 | 1869 | 0.150 |
Why?
|
Larynx | 1 | 2022 | 494 | 0.150 |
Why?
|
Fanconi Anemia | 1 | 2019 | 319 | 0.140 |
Why?
|
Fatigue | 1 | 2023 | 1531 | 0.140 |
Why?
|
Brain Neoplasms | 2 | 2015 | 8863 | 0.130 |
Why?
|
Radium | 1 | 2016 | 65 | 0.130 |
Why?
|
Hemangiopericytoma | 1 | 2016 | 77 | 0.130 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12354 | 0.130 |
Why?
|
Female | 27 | 2023 | 380194 | 0.130 |
Why?
|
Organs at Risk | 1 | 2017 | 346 | 0.130 |
Why?
|
Epithelium | 1 | 2019 | 1679 | 0.120 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 705 | 0.120 |
Why?
|
Prognosis | 7 | 2019 | 29063 | 0.120 |
Why?
|
Thyroidectomy | 1 | 2019 | 879 | 0.120 |
Why?
|
Pilot Projects | 2 | 2024 | 8324 | 0.120 |
Why?
|
Disease Progression | 4 | 2017 | 13284 | 0.110 |
Why?
|
Radiation Dosage | 1 | 2021 | 1928 | 0.110 |
Why?
|
Adult | 19 | 2020 | 214055 | 0.110 |
Why?
|
Mouth Neoplasms | 1 | 2018 | 601 | 0.110 |
Why?
|
Survival Rate | 6 | 2020 | 12788 | 0.110 |
Why?
|
Treatment Outcome | 13 | 2019 | 63114 | 0.110 |
Why?
|
Deglutition Disorders | 1 | 2017 | 605 | 0.100 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6171 | 0.100 |
Why?
|
Treatment Failure | 1 | 2017 | 2618 | 0.100 |
Why?
|
Salvage Therapy | 1 | 2018 | 1275 | 0.100 |
Why?
|
Stents | 1 | 2023 | 3280 | 0.100 |
Why?
|
Myocardial Infarction | 1 | 2012 | 11727 | 0.100 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5221 | 0.090 |
Why?
|
Blood Cells | 1 | 2012 | 309 | 0.090 |
Why?
|
Ultrasonics | 1 | 2011 | 212 | 0.090 |
Why?
|
Tomography, Optical Coherence | 2 | 2012 | 2657 | 0.090 |
Why?
|
Necrosis | 1 | 2013 | 1643 | 0.090 |
Why?
|
Time Factors | 4 | 2019 | 40075 | 0.080 |
Why?
|
Cell Line | 2 | 2021 | 15997 | 0.080 |
Why?
|
Databases, Factual | 3 | 2019 | 7729 | 0.080 |
Why?
|
Palliative Care | 1 | 2023 | 3493 | 0.080 |
Why?
|
Knee Injuries | 1 | 2013 | 490 | 0.080 |
Why?
|
Risk Assessment | 5 | 2020 | 23338 | 0.080 |
Why?
|
Genomics | 2 | 2021 | 5720 | 0.080 |
Why?
|
Kidney | 1 | 2023 | 7186 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2017 | 2635 | 0.070 |
Why?
|
Blood Coagulation | 1 | 2012 | 1127 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2019 | 2282 | 0.070 |
Why?
|
Tissue Plasminogen Activator | 1 | 2012 | 1261 | 0.070 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2011 | 496 | 0.070 |
Why?
|
Swine | 2 | 2013 | 5917 | 0.070 |
Why?
|
Linear Models | 1 | 2016 | 5952 | 0.070 |
Why?
|
DNA | 1 | 2019 | 7301 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2016 | 2737 | 0.060 |
Why?
|
Aortic Diseases | 1 | 2011 | 742 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2016 | 3474 | 0.060 |
Why?
|
Biopsy | 1 | 2016 | 6756 | 0.060 |
Why?
|
Logistic Models | 1 | 2019 | 13408 | 0.060 |
Why?
|
Knee Joint | 1 | 2013 | 1680 | 0.060 |
Why?
|
Equipment Design | 1 | 2012 | 3582 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12245 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2012 | 6365 | 0.060 |
Why?
|
Aorta | 1 | 2011 | 2061 | 0.060 |
Why?
|
Contrast Media | 2 | 2016 | 5300 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7913 | 0.050 |
Why?
|
Image Enhancement | 1 | 2013 | 2921 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2012 | 2158 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18370 | 0.050 |
Why?
|
Registries | 1 | 2017 | 8089 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 21746 | 0.050 |
Why?
|
Particle Accelerators | 1 | 2022 | 173 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6234 | 0.050 |
Why?
|
Mesenchymal Stem Cells | 1 | 2011 | 1632 | 0.050 |
Why?
|
Thrombosis | 1 | 2013 | 2968 | 0.040 |
Why?
|
Young Adult | 4 | 2019 | 56430 | 0.040 |
Why?
|
Observer Variation | 2 | 2017 | 2593 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12959 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2019 | 19905 | 0.040 |
Why?
|
Indazoles | 1 | 2019 | 289 | 0.040 |
Why?
|
Pelvis | 1 | 2022 | 730 | 0.040 |
Why?
|
Retinoblastoma Protein | 1 | 2021 | 704 | 0.040 |
Why?
|
Neck Dissection | 1 | 2019 | 197 | 0.040 |
Why?
|
Epidural Neoplasms | 1 | 2016 | 24 | 0.030 |
Why?
|
Retreatment | 1 | 2018 | 610 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2021 | 794 | 0.030 |
Why?
|
Androgens | 1 | 2024 | 1281 | 0.030 |
Why?
|
Liposarcoma, Myxoid | 1 | 2016 | 67 | 0.030 |
Why?
|
Thoracotomy | 1 | 1997 | 363 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2077 | 0.030 |
Why?
|
Survival Analysis | 2 | 2019 | 10252 | 0.030 |
Why?
|
Perfusion Imaging | 1 | 2017 | 195 | 0.030 |
Why?
|
Mastectomy | 1 | 2023 | 1793 | 0.030 |
Why?
|
DNA, Viral | 1 | 2021 | 2225 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2021 | 1149 | 0.030 |
Why?
|
SEER Program | 1 | 2019 | 1508 | 0.030 |
Why?
|
Morbidity | 1 | 2019 | 1769 | 0.030 |
Why?
|
Fibrosarcoma | 1 | 2016 | 348 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2022 | 2480 | 0.030 |
Why?
|
Emergency Treatment | 1 | 1997 | 517 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2023 | 5078 | 0.030 |
Why?
|
Transfection | 1 | 2021 | 5892 | 0.030 |
Why?
|
Cell Cycle | 1 | 2021 | 2967 | 0.030 |
Why?
|
Doxorubicin | 1 | 2019 | 2234 | 0.030 |
Why?
|
Rhabdomyosarcoma | 1 | 2016 | 382 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2017 | 2327 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 2728 | 0.030 |
Why?
|
Motion | 1 | 2016 | 798 | 0.030 |
Why?
|
Thyroid Gland | 1 | 2019 | 1173 | 0.030 |
Why?
|
Paclitaxel | 1 | 2019 | 1708 | 0.030 |
Why?
|
DNA Repair | 1 | 2021 | 2046 | 0.030 |
Why?
|
Genetic Loci | 1 | 2021 | 2575 | 0.030 |
Why?
|
Leiomyosarcoma | 1 | 2016 | 477 | 0.030 |
Why?
|
Pneumonectomy | 1 | 2018 | 1094 | 0.020 |
Why?
|
Risk | 1 | 2023 | 9687 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2948 | 0.020 |
Why?
|
Risk Factors | 1 | 2017 | 72290 | 0.020 |
Why?
|
Menisci, Tibial | 1 | 2013 | 269 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2021 | 3023 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3479 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2214 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 14722 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3616 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1938 | 0.020 |
Why?
|
Blood | 1 | 2012 | 598 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 1997 | 980 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2021 | 2020 | 0.020 |
Why?
|
Heart Arrest | 1 | 1997 | 1470 | 0.020 |
Why?
|
Pyrimidines | 1 | 2019 | 2942 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2017 | 2645 | 0.020 |
Why?
|
Arthroscopy | 1 | 2013 | 926 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8340 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2022 | 20129 | 0.020 |
Why?
|
Animals | 3 | 2013 | 168757 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 4851 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2017 | 3589 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2459 | 0.020 |
Why?
|
Oxygen | 1 | 2017 | 4189 | 0.020 |
Why?
|
Rabbits | 1 | 2011 | 4894 | 0.020 |
Why?
|
Cohort Studies | 2 | 2018 | 40561 | 0.020 |
Why?
|
Comorbidity | 1 | 2019 | 10388 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 8642 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 3327 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15076 | 0.010 |
Why?
|
Child, Preschool | 2 | 2023 | 41006 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2011 | 4776 | 0.010 |
Why?
|
Graft Survival | 1 | 2011 | 3737 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5985 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15540 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2012 | 4042 | 0.010 |
Why?
|
Adolescent | 3 | 2016 | 85781 | 0.010 |
Why?
|
Belgium | 1 | 1997 | 103 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2012 | 19229 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1997 | 1681 | 0.010 |
Why?
|
Rats | 1 | 2011 | 24260 | 0.010 |
Why?
|
Child | 2 | 2016 | 77709 | 0.010 |
Why?
|
United States | 1 | 2019 | 69872 | 0.010 |
Why?
|